Cholera vaccines - PubMed
- ️Invalid Date
Review
Cholera vaccines
E T Ryan et al. Clin Infect Dis. 2000 Aug.
Abstract
Cholera causes significant morbidity and mortality worldwide. For travelers, the risk of developing cholera per month of stay in a developing country is approximately 0.001%-0.01%, and cholera may present as traveler's diarrhea. In the United States, only a poorly tolerated, marginally effective, parenterally administered, phenol-inactivated vaccine is available. Outside the United States, 2 additional vaccines are commercially available: an oral killed whole cell-cholera toxin recombinant B subunit vaccine (WC-rBS) and an oral live attenuated Vibrio cholerae vaccine (CVD 103-HgR). These oral vaccines are well tolerated. In field trials, WC-rBS provides 80%-85% protection from cholera caused by V. cholerae serogroup O1 for at least 6 months. In volunteer studies, CVD 103-HgR provides 62%-100% protection against cholera caused by V. cholerae for at least 6 months. No commercially available cholera vaccine protects against disease caused by V. cholerae serogroup O139. New cholera vaccines are being developed.
Similar articles
-
A review of the current status of enteric vaccines.
Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
-
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. Levine MM, et al. Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
-
Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
Jackson SS, Chen WH. Jackson SS, et al. Future Microbiol. 2015;10(8):1271-81. doi: 10.2217/FMB.15.51. Epub 2015 Jul 31. Future Microbiol. 2015. PMID: 26228388
-
Current status of cholera and rise of novel mucosal vaccine.
Yamamoto T. Yamamoto T. Jpn J Infect Dis. 2000 Oct;53(5):181-8. Jpn J Infect Dis. 2000. PMID: 11135702 Review.
-
Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A, Ivanoff B, Svennerholm AM, Holmgren J, Clemens JD. Trach DD, et al. Bull World Health Organ. 2002;80(1):2-8. Bull World Health Organ. 2002. PMID: 11884967 Free PMC article. Clinical Trial.
Cited by
-
Newer insights into the mechanism of action of Psidium guajava L. leaves in infectious diarrhoea.
Birdi T, Daswani P, Brijesh S, Tetali P, Natu A, Antia N. Birdi T, et al. BMC Complement Altern Med. 2010 Jun 28;10:33. doi: 10.1186/1472-6882-10-33. BMC Complement Altern Med. 2010. PMID: 20584265 Free PMC article.
-
Bacterial infectious disease control by vaccine development.
Curtiss R 3rd. Curtiss R 3rd. J Clin Invest. 2002 Oct;110(8):1061-6. doi: 10.1172/JCI16941. J Clin Invest. 2002. PMID: 12393839 Free PMC article. Review. No abstract available.
-
Diagnosis, Management, and Future Control of Cholera.
Chowdhury F, Ross AG, Islam MT, McMillan NAJ, Qadri F. Chowdhury F, et al. Clin Microbiol Rev. 2022 Sep 21;35(3):e0021121. doi: 10.1128/cmr.00211-21. Epub 2022 Jun 21. Clin Microbiol Rev. 2022. PMID: 35726607 Free PMC article. Review.
-
Vaccines against human diarrheal pathogens: current status and perspectives.
Böhles N, Böhles N, Busch K, Busch K, Hensel M, Hensel M. Böhles N, et al. Hum Vaccin Immunother. 2014;10(6):1522-35. doi: 10.4161/hv.29241. Epub 2014 May 26. Hum Vaccin Immunother. 2014. PMID: 24861668 Free PMC article. Review.
-
Williams HA, Gaines J, Patrick M, Berendes D, Fitter D, Handzel T. Williams HA, et al. PLoS One. 2015 Nov 12;10(11):e0142778. doi: 10.1371/journal.pone.0142778. eCollection 2015. PLoS One. 2015. PMID: 26562658 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical